Editorial
|
|
|
|
|
Solid evidence is needed before approving "personalised medicine"
|
|
|
|
Marketing Authorisations
|
|
|
|
|
Too toxic
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No comparison with spironolactone
|
|
|
|
|
|
|
|
|
|
No tangible efficacy but a risk of immunosuppression
|
|
|
|
|
|
|
|
|
|
More dangerous than beneficial
|
|
|
|
|
|
|
|
|
|
Beware the potentially serious adverse effects of exenatide
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
Avoid routine calcium supplementation
|
|
|
|
|
|
|
|
|
|
Harm-benefit balance of eye drops should be reviewed regularly
|
|
|
|
|
|
|
|
|
|
A few cases reported by EMA
|
|
|
|
|
|
|
|
|
|
|
|
Unfavourable harm-benefit balance
|
|
|
|
Reviews
|
|
|
|
|
No antidote, and little clinical experience
|
|
|
|
|
|
|
|
|
|
|
|
More than 15 hours of oxygen per day
|
|
|
|
|
|
|
|
|
|
|
|
Alternative procedures should be discussed
|
|
|
|
Outlook
|
|
|
|
|
Results often fall short of expectations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subconscious and effective
|
|
|
|
|
|
|
|
|
|
Prescrire's annual financial report
|
|
|
|
|
|